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Abstract
Objective The primary aim of the study was to analyze
the endometrioma recurrence rate in patients who under-
went laparoscopic excision followed by postoperative long-
term regimen of oral contraceptives (OCs).
Materials and methods 168 patients who underwent a
conservative laparoscopic surgery for endometrioma, dur-
ing the period between September 2009 and August 2010
in three university hospitals were studied. A long-term OCs
therapy was offered to all women following surgery.
Patients were randomly divided into three groups accord-
ing to different progestins used (desogestrel, gestodene,
dienogest). Women who refused a postoperative hormonal
therapy served as control. Follow-up visits and transvaginal
scan were planned at 1, 3, 6, 12, and 24 months after
surgery. All patients who showed an ultrasound persistence
of the endometrioma at 1 month follow-up were excluded
from clinical analysis.
Results Of the 168 patients, 131 completed the
24 months follow-up. Endometrioma recurrence was found
in 21 (12.5 %) of all patients, it was unilateral in 17 cases
while bilateral in 4 cases. The rate of recurrent endome-
trioma was statistically significant in non-users compared
to the long-term OCs treated patients.
Conclusion The current data suggest the usefulness of
long-term OCs regimen after conservative surgery for the
prevention of ovarian endometrioma recurrence. As a sta-
tistical significant difference could not be observed
between OCs groups, further study on the individual mol-
ecules is required in order to really understand the effect of
each of them.
Keywords Endometriosis  Endometrioma recurrence 
Oral contraceptives  Minimally invasive gynaecologic
surgery  Progestins  Dienogest
Introduction
Endometriosis is an interesting, chronic disease caused by
the growth of functional endometrial-like tissue outside the
uterus, which in turn causes infertility and pelvic pain, and
affects up to 10 % of women of reproductive age [1].
Ovary is the most common organ involved (in *55 % of
cases [2]). ‘‘Unfortunately, there is no permanent cure for
this condition, so it often requires a life-long management
plan with the goal of maximizing the use of medical
treatment and avoiding repeated surgical procedures’’,
reports the American Society of Reproductive Medicine
[3]. Lesions and symptoms very frequently return after
medication is discontinued or after conservative surgery is
performed, a fact which frustrates both patients and clini-
cians [4] and is estimated to occur in 30–50 % of cases
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within 2–5 years [2, 5–10]. The American College of
Obstetricians and Gynecologists Practice Bulletin suggests
that the true recurrence rate must be even higher than the
rate generally reported in literature, because most publi-
cations report symptomatic disease only [11]. Conservative
laparoscopic surgery is considered to be the gold standard
for the treatment of ovarian endometriosis [12–17]. There
is general agreement that endometrioma removal increases
the likelihood of conception [18, 19], and recent evidence
shows that both the presence of an endometrioma and its
surgical excision may impair ovarian reserve and, there-
fore, future fertility [20, 21], especially after a second
operation. Although surgery is cytoreductive, it does not
prevent recurrence, so therapeutic strategies should be
found based on factors which affect the natural course of
the disease and its tendency to reappear [5].
Moreover, since long-term medical therapy is necessary,
consideration has been given not only to efficacy, but also
to the long-term safety and tolerability of the treatment
options available. For these reasons, oral contraceptives
(OCs) have been widely used in many countries to treat the
most common symptoms of endometriosis [22].
Some studies have reported that monophasic oral con-
traceptive treatment either to reduce retrograde menstrual
cycles or to inhibit ovulation—which are both considered
etiopathogenetic factors for endometriosis—may also
suppress the recurrence of endometrioma when adminis-
tered long term after conservative surgery [2, 5, 10, 16, 23].
Progestogens have a crucial role in decreasing endometri-
otic lesions, through a number of mechanisms which may
vary in type and intensity according to the different mol-
ecules. They may prevent implantation and growth of
regurgitated endometrium inhibiting expression of matrix
metalloproteinases and angiogenesis, and have several anti-
inflammatory in vitro and in vivo effects that may reduce
the inflammatory state generated by the metabolic activity
of the ectopic endometrium, and the consequent immune
response [24]. For this reason, new progestins are contin-
ually tested, in an attempt to find the perfect drug which
ensures the desired effects without side effects. Two recent
clinical studies in Europe and Japan extensively investi-
gated a new treatment for endometriosis using Dienogest, a
19-nortestosterone derivative that is highly selective for
progesterone receptors [25]. The studies demonstrated that
at 2 mg daily, this progestin effectively alleviates pain,
reduces endometriosis lesions and improves quality of life
[26]. Our controlled randomized study based on these
reports was intended to analyze the recurrence rate of
endometrioma in patients who had undergone laparoscopic
excision and a long-term postoperative regimen of OCs to
verify their effectiveness in preventing the disease. We also
sought to establish whether a different progestin in the oral
contraceptive could control recurrence in a different
manner. Thus, we administered three types of OCs, which
included dienogest.
Materials and methods
This multi-centre study was conducted in the Departments
of Obstetrics and Gynaecology at the Universities of
Naples, Messina and Palermo, Italy. A total of 168 patients
who had undergone conservative surgery for ovarian
endometrioma between September 2009 and August 2010
were enrolled. Permission was obtained from the Local
Institutional Review Board before the study began.
Women between 18 and 40 years, not attempting to
conceive, either at the time of study entry or for at least
2 years after surgery, were included in the study. We
excluded patients who had previously undergone surgical
treatment for endometriosis or had taken recent medical
treatment for this pathology. Therefore, none of them had
been receiving OCs for at least 6 months before surgery.
We also excluded patients with contraindications to OCs
therapy or who did not wish to postpone pregnancy for at
least 2 years after surgery.
After transvaginal ultrasound diagnosis, the women
underwent laparoscopic excision of the endometrioma
using the so-called ‘‘stripping technique’’. The procedures
were performed by surgeons with expertise in minimally
invasive gynaecologic surgery listed as Level II by the
SEGI (Italian Society of Gynaecologic Endoscopy). The
staging of the endometriosis was carried out using the
procedure specified by the American Society for Repro-
ductive Medicine (ASRM) [27].
Upon hospital discharge, long-term therapy (24 months)
with OCs was offered to all patients, who were advised that
inhibition of ovulation may potentially reduce the risk of
recurrence, according to recent medical evidence. They
were asked to participate in the study and signed an
informed consent form. Treatment allocation was per-
formed in accordance with a computer-generated random-
ization sequence with the use of numbered, opaque, sealed
envelopes.
The primary aim of the study was to assess any statis-
tical differences of clinical import among the types of
progestins used. Two monophasic and one multiphasic OC
were selected. Patients who did not accept the treatment
protocol were considered to be ‘‘non-users’’ (Group A, 38
patients) and were scheduled to undergo the same follow-
up protocol.
The remaining 130 patients were randomly divided into
three subgroups according to progestin type: monophasic
pill with EE 20 lg and 0.15 mg desogestrel daily
(Group B, 43 patients); monophasic pill with EE 20 lg and
gestodene 0.075 mg daily (Group C, 44 patients); and
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multiphasic pill with 2 mg E2V for 22 days, with 2 mg
dienogest for the first 5 days and 3 mg on the remaining
17 days, the other four: pill with only E2V and two: pla-
cebo pill (Group D, 43 patients). The patients were fol-
lowed up with a clinical examination and a transvaginal
ultrasonographic scan, for at least 24 months. Follow-up
visits were planned at 1, 3, 6, 12, and 24 months after
surgery. All the scans were performed by experienced
operators, blinded to the study allocation.
The secondary aim of the study was to assess the timing
of recurrence by calculating (in months) the reappearance
of the ovarian endometrioma after surgery.
The presence of an endometrioma 1 month after sur-
gery, as diagnosed by transvaginal ultrasound, was con-
sidered to be persistence of the disease, and these patients
were excluded from follow-up. The diagnostic ultrasono-
graphic criteria established by Mais et al. [28] for endo-
metrioma recurrence were used.
Statistical analysis
Statistical analysis using Primer (version 5.0) was con-
ducted by an independent physician (GT) who was aware
of patient outcome and randomization. The data were
expressed as mean ± SD. The differences in normally
distributed values between two groups were assessed using
the Student paired t test. Analysis of variance (ANOVA)
was used when appropriate. Kaplan–Meier curves were
generated to assess the rate of recurrent endometriosis, and
the log-rank test was performed to assess the difference in
the rate of recurrence between different treatments. The
power of study was 80 % and the statistically significant
difference was defined as p \ 0.05.
Results
The mean age of the women taking part in the study was
29 ± 2.3 years, and the mean parity was 0.96. At the time
of surgery, we observed a bilateral and a monolateral
endometrioma in 37 and 63 % of cases, respectively
(Table 1). Also, pelvic adhesions were present in 90 % of
cases. No intraoperative complications occurred during
surgery; no abdominal conversion was needed.
Before surgery, all women were classified as having
stage III or stage IV endometriosis. Endometriosis recur-
rence occurred in 21 (12.5 %) out of the 168 women
examined (95 % CI, 8–18 %). One hundred and thirty-one
patients reached the 24 month follow-up.
Recurrence of the endometrioma was unilateral and
bilateral in 17 and 4 cases, respectively, with the latter
observed in Group A and Group B, only.
Eight ‘‘non-users’’ (21 %) did not complete the study:
two of them achieved spontaneous pregnancy before
24 months of follow-up, two started to receive OCs therapy
because of referred dysmenorrhoeal, three for causes
unrelated to the study and one was excluded for cyst per-
sistence at 1 month of follow-up. Twenty-nine patients
(22 %) among the user groups (groups B, C and D) did not
complete the study: 14 of them for causes unrelated to the
study, 11 of them for side effects attributable to OCs
therapy, four of them were excluded for cyst persistence at
1 month of follow-up (see also Table 2 and flow diagram).
The main side effects using OCs reported by the 11
women who did not complete the treatment for these rea-
sons, comparable in all three groups of users, exactly, were:
headache in ten patients, decreased libido in nine patients,
spotting in six patients, water retention in four patients,
vaginal dryness in two patients, depression in one patient,
acne in one patient, insomnia in one patient. The charac-
teristics of the menstrual bleeding profile during treatment
are reported in Table 3. The rate of endometrioma recur-
rence was statistically significant in Group A compared
with Group B (p = 0.0021; relative risk: 4.85; 95 % CI:
1.77–13.28), Group C (p = 0.0009; relative risk: 5.73;
95 % CI: 2.04–16.09) and Group D (p \ 0.0001; relative
risk: 9.16; 95 % CI: 3.05–27.53), respectively (Fig. 1). The
cumulative probability of cyst recurrence was 74.7 % in
group A, 26.5 % in group B, 31.8 % group C and 20.5 %
Table 1 Characteristics of the 168 eligible patients
Group A (non-users) Group B Group C Group D
Number of patients 38 43 44 43
Average age ± SD (years) 30.2 ± 2.1 29.6 ± 2.7 28.5 ± 1.8 27.8 ± 1.9
BMI ± SD (kg/m2) 20.8 ± 2.3 21.2 ± 2.4 21.4 ± 2.7 20.5 ± 2.5
American Fertility Society stage
III 16 18 20 22
IV 22 25 24 21
Mean preop. cyst diameter ± SD (cm) 4.1 ± 0.42 4.9 ± 0.65 4.8 ± 0.57 5.1 ± 0.6
Bilateral cyst 13 15 17 17
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in group D. In cases of recurrence, endometrioma diameter
was higher in Group A compared with Group B
(3.1 ± 0.42 vs 1.9 ± 0.65 cm; p \ 0.0001), as well as
with Group C (3.1 ± 0.42 vs 1.8 ± 0.57 cm; p \ 0.0001)
(Fig. 2).
Discussion
Effective long-term management of endometriosis is a
significant goal, given the debilitating nature of this con-
dition. Recurrence is very common after surgery, varying
from 29 to 56 % [2, 10, 29], while evidence to support the
efficacy and safety of many medications used to treat it is
lacking [26].
Retrograde menstruation seems to be the most probable
pathogenetic mechanism behind the development of this
pathology [1, 5, 30, 31]. Decreasing or eliminating the
menstrual cycle (and tubaric reflux as a result) through the
use of cyclic or continuous OCs may reduce the probability
of cyst recurrence or peritoneal reimplantation [5]. The
efficacy of postoperative OCs treatment is also supported
by the theory that anovulation and moderately low oest-
rogen concentration may induce atrophy of the endome-
triotic implants [32], reduce disease-related pain [16],
down-regulate cell proliferation and enhance programmed
cell death (apoptosis) in the endometrium, which is
abnormally low in women with endometriosis [33].
Moreover, it has been hypothesized that since ovulation
is causally related to endometriotic cyst development [10,
19, 20], ovarian suppression may reduce the risk of
recurring lesions.
The mechanisms reported above have been the subject
of recent studies that assess the effectiveness of long-term
Table 2 Persistence (at 1 month of follow-up) and recurrence of endometrioma during the 24 months of follow-up
Total number of patients 1 month 3 months 6 months 12 months 24 months
Group A: 38 pts 2/37 1/34 7/32 4/30 1/30
Group B: 43 pts 0/42 0/42 1/39 2/36 1/35
Group C: 44 pts 1/44 1/43 1/41 1/35 0/33
Group D: 43 pts 1/40 0/39 0/38 1/36 0/33
Table 3 Characteristics of the menstrual bleeding profile in the three groups during treatment
Average day flow Dysmenorrhoea (%) Spotting (%) Average cadency
Group A 5 56 0 28 ± 5
Group B 4 7 25 26 ± 2 (OCs users)
Group C 4 10 32 26 ± 3 (OCs users)
Group D 3 0 15 27 ± 2 (OCs users)
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OCs administration in preventing ovarian endometrioma
recurrence [2], thus offering a valuable alternative to serial
surgery [24, 34, 35]. A recent randomized controlled trial
[36] examined the effect of postoperative OCs on endo-
metrioma recurrence. The study established that 6-month
OCs therapy after surgery tends to prevent recurrence at
12 months after surgery, but does not significantly influ-
ence recurrence of the disease at 24- and 36-month follow-
up [36]. In yet another study, it was found that mean
postoperative treatment of *9 months did not significantly
influence recurrence; however, the authors suggested that a
longer period of treatment may have an effect on its pre-
vention [6]. Other authors have pointed out that long-term
cyclic and continuous OCs use effectively reduces and
delays recurrence [2, 10]. Long-term exposure to OCs has
been associated with a greater reduction in the risk of
recurrence, which is directly proportional to the duration of
therapy [35].
In our sample of patients, postoperative OCs treatment
was administered long term. Treatment was performed
cyclically because according to several authors [2], no
statistically significant difference has been demonstrated
between cyclic and continuous use as far as number, size,
and growth of recurrent endometrioma are concerned.
Furthermore, we chose cyclic administration because it was
more easily accepted by patients from the psychological
standpoint, since it results in a regular cycle. In literature, a
positive trend has also been reported in patients receiving
continuous therapy [2, 35]. This may be due to its constant
hormonal environment, which could increase the effec-
tiveness of the therapy [35].
As previously found in other studies [2, 10, 34, 35], we
observed a significant reduction in the risk of postoperative
endometrioma recurrence in patients who underwent lap-
aroscopic excision and long-term postoperative use of
cyclic OCs, compared with patients who did not receive
such treatment.
According to another study [24], the progestins con-
tained in the OCs are the most effective hormones against
endometriosis, as they may prevent the implantation and
growth of regurgitated endometrial cells by inhibiting the
expression of matrix metalloproteinases and angiogenesis.
This reduces the inflammatory state generated by ectopic
endometrium and the consequent immune response [24],
which is considered the primary causative factor behind
endometriosis [37]. For this reason, we tried to understand
whether all progestins play the same role or one type is
more active than the others. We decided to compare two
monophasic pills containing desogestrel and gestodene,
respectively, because they are the only OCs used in
European studies dealing with this topic. Moreover,
according to some authors [38], the use of desogestrel
showed a significant decrease in cell proliferation and an
increased apoptosis in the ectopic endometrial tissue.
Another study on OCs containing gestodene showed a
decrease in aromatase expression in the eutopic endome-
trium of patients with endometriosis [39]. Aromatase
expression in the endometrium seems to play a pivotal role
in the development of endometriotic lesions. Because
inflammatory mediators such as prostaglandin E2 appear to
activate aromatase in the cells of the endometrial stroma, it
was hypothesised that the ensuing inflammation caused by
the arrival of aromatase-positive cells in the peritoneal
cavity would stimulate local oestrogen production, which
would in turn facilitate the development of endometriotic
lesions by suppressing macrophage phagocytosis [40].
Moreover, our study was also designed to verify the
efficacy of an OC containing dienogest, an oral progestin
that has recently been investigated for the treatment of
endometriosis in a dose-ranging study and in long-term
trials in Europe and Japan [26]. Also, it has been approved
as a monotherapy for the treatment of this pathology in
various countries [26]. Dienogest binds to the progesterone
receptor with high specificity and produces a powerful
Fig. 1 Kaplan–Meier curves showing the rate of recurrent endome-
triosis in Group A (nonusers), Group B (monophasic desogestrel),
Group C (monophasic gestodene), Group D (Klaira modified to
biphasic)
Fig. 2 The bar graph shows the variation in the diameter of recurrent
endometrioma (mean ± SD) in the four subgroups who underwent
clinical follow-up
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progestogenic effect [41]. When administered continu-
ously, it results in anti-ovulatory activity [42], inhibitory
effects on cytokine production of endometriotic cells [43],
a hypoestrogenic endocrine environment, and decidual-
ization of endometrial tissue and consequent atrophy of the
endometriotic lesions [26] without androgenic effects and
with minimal changes in lipid and carbohydrate levels [44,
45]. For these reasons, a therapeutic effect against endo-
metriosis was expected.
In a recent multi-centre study, a multiphasic OC with
dienogest was considered to be very active in reducing
endometriosis pain over the long term; i.e., for at least
24 weeks after discontinuation of treatment [22].
Therefore, we compared two monophasic OCs con-
taining two different progestins and a multiphasic OC with
dienogest. We found that the type of progestin used did not
influence recurrence time in treated patients. It is possible
that when administered in association with oestrogen, as in
the OCs tested in our study, Dienogest is not significantly
superior, even though an improved curative trend was
observed in the group treated with OCs containing this
progestin.
The selection of persistent instead of recurrent cysts was
avoided by excluding patients who still presented a cyst at
1-month follow-up. Moreover, scanning was performed
only by highly qualified sonographers with extensive
experience in the detection of endometriotic lesions.
The protective effect of OCs seems to fade quickly after
discontinuation of therapy [10, 36], which suggests that the
use of OCs be continued until pregnancy is desired [5].
After recurrent surgery, the likelihood of conception has
been reported to be almost 50 % lower than after the pri-
mary surgery [46–49].
OCs are the only medications which inhibit ovulation,
are well tolerated and safe in long-term use, and are also
economical [34]. Moreover, OCs prevent the recurrence of
pain, improve quality of life, allow conception after dis-
continuation of treatment, and protect against ovarian
cancer associated with endometriosis [50].
Unfortunately, there are some limitations in the current
study. One of them is that the number of patients collected
is not large enough to draw definitive conclusions. More-
over, we focused the study on cyst recurrence without
considering its correlation with symptoms. Further studies
on the postoperative use of OCs, considering both aspects,
seem therefore necessary to support the suggested therapy.
Another limit of our study is that a good comparison of
the effect of the two progestins contained in the OCs with
the one with dienogest, to establish the stronger effect on
endometrioma recurrence, is not really possible. In fact, the
pill with dienogest is combined with natural oestradiol and
not with EE, as in the other two OCs, therefore, the nature
of the oestrogen could interfere with the different
endometriosis inhibition. But, as we did not obtain a sig-
nificant difference between the three groups, further study
on the individual molecules is required in order to really
understand the effect of each of them.
Based on the review of medical literature and our
observations, a few clinical considerations can be made: (1)
in case of recurrence, the endometrioma diameter was
higher in patients who had refused postoperative OCs; (2)
OCs may potentially reduce the severity of the disease; (3)
although no statistical difference was reported for endo-
metrioma diameter among patients using different types of
progestins in cyclic OCs therapy, better results were
observed in patients treated with dienogest; (4) conserva-
tive surgery is the first-line treatment in case of endome-
trioma, with the second step possibly being to encourage
women to become pregnant and/or to prevent endometri-
oma recurrence with OCs, regardless of the type of prog-
estins used.
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